Rhenman & Partners Asset Management Ab Decreased Pfizer Inc (NYSE:PFE) Stake By $14.70 Million

October 13, 2017 - By Jacob Falcon

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.01, from 0.95 in 2017Q1. It is negative, as 58 investors sold PFE shares while 716 reduced holdings. 112 funds opened positions while 612 raised stakes. 4.02 billion shares or 1.07% less from 4.06 billion shares in 2017Q1 were reported. C Worldwide A S holds 0.29% of its portfolio in Pfizer Inc. (NYSE:PFE) for 570,202 shares. City Holdg Com reported 0.93% in Pfizer Inc. (NYSE:PFE). Texas Permanent School Fund reported 0.74% of its portfolio in Pfizer Inc. (NYSE:PFE). Fagan Assoc Incorporated has invested 0.58% in Pfizer Inc. (NYSE:PFE). The North Carolina-based Sterling Capital Mngmt Llc has invested 0.69% in Pfizer Inc. (NYSE:PFE). Moreover, New England Research & has 1.75% invested in Pfizer Inc. (NYSE:PFE). Chesley Taft Assocs Limited Com holds 0.71% or 232,875 shares in its portfolio. Reliance Trust Of Delaware holds 99,832 shares. Df Dent holds 30,968 shares. Quantitative Systematic Strategies Ltd Com invested in 0.37% or 42,897 shares. First Mercantile Tru Company has 0.14% invested in Pfizer Inc. (NYSE:PFE) for 23,000 shares. Pekin Singer Strauss Asset Management Il holds 81,581 shares. Boyar Asset Management, New York-based fund reported 152,806 shares. Walleye Trading Limited Liability Company invested in 375,795 shares. Wedge Capital Mgmt L Lp Nc invested in 0% or 6,366 shares.

Rhenman & Partners Asset Management Ab decreased its stake in Pfizer Inc (NYSE:PFE) by 97.58% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 420,000 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 10,422 shares of the health care company at the end of 2017Q3, valued at $372,000, down from 430,422 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $216.41 billion market cap company. The stock declined 0.08% or $0.03 reaching $36.31 per share. About 12.77 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since October 14, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 20 analysts covering Pfizer (NYSE:PFE), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Pfizer has $54.0 highest and $3300 lowest target. $38.63’s average target is 6.39% above currents $36.31 stock price. Pfizer had 59 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Friday, August 14. The firm has “Neutral” rating given on Thursday, July 20 by Credit Suisse. The firm earned “Neutral” rating on Friday, December 2 by Guggenheim. The stock has “Overweight” rating by Morgan Stanley on Wednesday, September 20. The firm has “Market Perform” rating by Leerink Swann given on Monday, May 2. BMO Capital Markets maintained the stock with “Hold” rating in Friday, April 28 report. Berenberg initiated the stock with “Hold” rating in Thursday, May 12 report. Jefferies maintained the stock with “Buy” rating in Thursday, August 4 report. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) rating on Saturday, September 5. Piper Jaffray has “Overweight” rating and $51 target. The rating was downgraded by BMO Capital Markets to “Market Perform” on Wednesday, November 2.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has market cap of $216.41 billion. The Firm is engaged in the discovery, development and manufacture of healthcare products. It has a 26.47 P/E ratio. The Company’s global portfolio includes medicines and vaccines, as well as consumer healthcare products.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Fool.com which released: “Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb” on September 17, 2017, also Bloomberg.com with their article: “Pfizer Spins Off New Firm for Some Rare Disease Drugs” published on September 25, 2017, Seekingalpha.com published: “Pfizer: A Good Buy” on October 02, 2017. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: Growth Trajectory Locked, Ready For Launch” published on October 09, 2017 as well as Seekingalpha.com‘s news article titled: “Recent Buy: Pfizer Inc.” with publication date: September 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.